CT Imaging for Guiding PA-TACE for HCC

Completed

• Conditions: Carcinoma, Hepatocellular

• Registration Number: NCT06156748
• Lead Sponsor: Zhujiang Hospital

Brief Summary

Postoperative adjuvant transarterial chemoembolization (PA-TACE) may improve survival outcomes in a subset of patients with resected hepatocellular carcinoma (HCC), reliable biomarkers for the criterion for the selection of candidates are lacking. The present study aimed to evaluate whether CT imaging can provide more value for predicting benefit from PA-TACE.

Detailed Description

Not available

Study Timeline

• Study Start: 2019-10-01
• Status Verified: 2023-11
• Study First Submitted: 2023-11-23
• Study First Submitted QC: 2023-11-30
• Study First Posted: 2023-12-05
• Primary Completion: 2025-06-30
• Study Completion: 2025-06-30
• Last Update Submitted: 2025-07-24
• Last Update Posted: 2025-07-28

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 1770

Inclusion Criteria

• CT scans acquired no more than one month before surgery
• Confirmation of HCC diagnosis by pathological examination
• Curative surgical resection

Exclusion Criteria

• Prior antitumor treatment
• Macrovascular thrombosis or metastasis
• Perioperative mortality
• Unqualified image artifacts
• Tumor rupture
• MVI status not reported

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Overall survival	the date of hepatectomy to the last follow-up or until death, whichever came first, assessed up to 120 months.	Overall survival was calculated from the date of hepatectomy to the last follow-up or until death, whichever came first.

Trial Locations

Locations (1)

ZhuJiang Hospital of Southern Medical University; 🇨🇳 Guangzhou, Guangdong, China